IP Library Granted Patent US 11,213,488
Granted Patent B2
US 11,213,488 · App. 15/872,727 · Granted Jan 4, 2022

Spray-dried blood products and methods of making same

Inventors: Thomas H. Fischer (Durham, NC); Joseph A. DaCorta (Durham, NC); Michael Lawrence Galiger (Durham, NC)
Assignee: Entegrion, Inc.
A61K9/1688A61F13/00063A61K9/0026A61K35/16A61K35/19A61L15/40A61L26/0047A61L26/0057A61L26/0076A61F2013/00306A61F2013/00472A61F2013/00927
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,213,488
App. No.
15/872,727
Granted
Jan 4, 2022
Kind
B2
Abstract

The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.

Claims (15)

1. A method of treating a patient suffering from a blood-related disorder, comprising the steps of:

a. preparing a dehydrated plasma blood product through a method comprising the steps of:

1. providing hydrated plasma having clotting factors with measurable clotting factor levels of concentration and activity; and

2. spray-drying said hydrated plasma at a temperature between about 110° C. to about 140° C. to produce a dehydrated plasma blood product wherein said clotting factors are preserved;

3. measuring said clotting factor levels after said spray-drying; and

4. comparing said clotting factor measurements, wherein said clotting factor levels of concentration and activity of said hydrated plasma and of said dehydrated plasma are essentially the same;

b. rehydrating a therapeutic amount of the dehydrated plasma blood product to produce a rehydrated therapeutic composition; and

c. administering said rehydrated therapeutic composition to said patient.

2. The method of claim 1 , wherein said hydrated plasma is physically or chemically modified.

3. The method of claim 2 , wherein said modification is chemical fixation.

4. The method of claim 2 , wherein said modification comprises additional diagnostic or therapeutic reagents.

5. The method of claim 4 , wherein said diagnostic or therapeutic reagents are selected from the group consisting of imaging agents, concentration factors, performance enhancement drugs, antimicrobial and antiviral reagents, universal donor solutions, and combinations thereof.

6. Spray dried plasma formed by the process of:

a) providing hydrated plasma; and

b) spray-drying said hydrated plasma directly by a spray dryer, wherein when said spray dried plasma has clotting factor levels of concentration and activity that are essentially the same as said hydrated plasma.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2025
From: ENTEGRION, INC
To: VELICO MEDICAL, INC
Reel/Frame 072096/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2025
From: DACORTA, JOSEPH A; FISCHER, THOMAS H; GALIGER, MICHAEL L
To: ENTEGRION, INC.
Reel/Frame 072096/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2022
From: ENTEGRION, INC.
To: VELICO MEDICAL, INC.
Reel/Frame 061250/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT APPLICATION NUMBER 15772727 SHOULD BE 15872727 PREVIOUSLY RECORDED ON REEL 044638 FRAME 0846. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 13, 2018
From: FISCHER, THOMAS H.; DACORTA, JOSEPH A.; GALIGER, MICHAEL L.
To: ENTEGRION, INC.
Reel/Frame 047508/0203 →
Continuity (3)
Continuation 13262931
Provisional Application 61212321 · Apr 9, 2009
Related Publication 20180153811A1 · Jun 7, 2018
Cited By (18)
US 12,201,920 US 12,208,121 US 12,246,093 US 12,246,266 US 12,247,784 US 12,253,308 US 12,274,955 US 12,337,260 US 12,405,057 US 12,414,920 US 12,447,244 US 12,529,518 US 12,533,602 US 12,533,603 US 12,533,604 US 12,535,269 US 12,539,355 US 12,571,587